TESOFENSINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H23Cl2NO
Molecular Weight	328.277
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC(Cl)=C(Cl)C=C3)N2C

InChI

InChIKey=VCVWXKKWDOJNIT-ZOMKSWQUSA-N

InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H23Cl2NO
Molecular Weight	328.277
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18474731 | https://www.ncbi.nlm.nih.gov/pubmed/11763162 | https://www.ncbi.nlm.nih.gov/pubmed/24239329

Tesofensine (also known as NS-2330) is a novel triple monoamine reuptake inhibitor with intrinsic inhibitory activity on norepinephrine (NE), serotonin (5-HT), and dopamine (DA) transporter function. It was development by NeuroSearch as a potential therapy for Alzheimer's disease (AD) and Parkinson's diseases, but these efforts have been discontinued. In phase II clinical trials with tesofensine in obese individuals, dose-related reductions in body weight, body fat and waist circumference, as well as improvements in other obesity-related endocrine factors were observed and the FDA recently endorsed the phase III trial program for this agent.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine transporter 180 Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24239329	Blocker 537

Conditions

Condition	Modality	Highest Phase	Product
Parkinson's disease 226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17149725	Primary	Phase II 1132	Unknown Approved Use Unknown
Alzheimer’s disease 272 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11763162	Primary	Phase II 1132	Unknown Approved Use Unknown
Obesity 203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19548858	Primary	Phase II 1132	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
1 mg 1 times / day multiple, oral Highest studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18950853/	unhealthy n = 49 Health Status: unhealthy Condition: obesity Sex: M+F Food Status: UNKNOWN Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/18950853/	Disc. AE: Mood altered, syncope... Other AEs: Nausea, vomiting... AEs leading to discontinuation/dose reduction: Mood altered (8%) syncope (2%) Vertigo (2%) Vertigo2 (16%) Pain of skin (2%) Hypervigilance (2%) Ear and labyrinth disorders (2%) Other AEs: Nausea (22.4%) vomiting (4.1%) Dry mouth (59.2%) Toothache (4.1%) Abdominal pain (12.2%) Diarrhoea (18.4%) Constipation (16.3%) Faeces hard (10.2%) Faecaloma (6.1%) Insomnia (16.5%) Dyssomnia (2%) Hypervigilance (6.1%) Dizziness (12.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/18950853/

AEs

PubMed

Title	Date	PubMed
Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation.	2007	18301726
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.	2007 Feb 15	17149725
Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine.	2007 Jan 26	17112503
Gateways to clinical trials.	2007 Jan-Feb	17344945
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.	2007 Jul	17324246
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.	2008 Jan	17982477
Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.	2008 Jun	18356831
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.	2008 May	18474731
Is new hope on the horizon for obesity?	2008 Nov 29	19041787
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.	2008 Nov 29	18950853
Gateways to clinical trials.	2008 Oct	19088949
Tesofensine and weight loss.	2009 Feb 28	19249626
Tesofensine and weight loss.	2009 Feb 28	19249625
Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13.	2009 Jul	19548858
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].	2009 Oct 5	19824222
[Is there a future for medical treatment of obesity?].	2009 Oct 5	19814923
Gateways to clinical trials.	2009 Sep	19907722
[Drug treatment of obesity--current situation and perspectives].	2010	21391349
Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.	2010	20000889
Tackling obesity: new therapeutic agents for assisted weight loss.	2010 Apr 26	21437080
[Recent progress and novel perspectives on obesity pharmacotherapy].	2010 Aug	20857056
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.	2010 Jul	20520602
Effect of centchroman coadministration on the pharmacokinetics of metformin in rats.	2010 Jun	20871764
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.	2010 Jun	20200509
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.	2010 Jun	20077053
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.	2010 Jun 25	20385125
Pharmacological management of appetite expression in obesity.	2010 May	20234354
New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?	2010 Nov	20688100
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.	2010 Nov	20479765

Patents

Sample Use Guides

In Vivo Use Guide

tesofensine 0.5 mg may cause almost double the weight loss

Route of Administration: Oral

In Vitro Use Guide

In vitro investigations resulted in IC50 values for tesofensine of 11 and 1.7 nM for the [3 H]5-HT and [3 H]noradrenaline uptake, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:57:46 UTC 2023` Edited by `admin` on `Sat Dec 16 16:57:46 UTC 2023`
Record UNII	BLH9UKX9V1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TESOFENSINE

Official Name

English

NS2330

Code

English

TESOFENSINE [MI]

Common Name

English

tesofensine [INN]

Common Name

English

Tesofensine [WHO-DD]

Common Name

English

NS-2330

Code

English

TESOFENSINE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C265